Good morning, welcome to the SWK Holdings Corporation First Quarter 2023 Financial Results Conference Call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing Star, then zero on your telephone keypad. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press Star then one on your telephone keypad. To withdraw your question, please press Star then two. Please note this event is being recorded. I would now like to turn the conference over to Jason Rando with Tiberend Strategic Advisors. Please go ahead. Good morning, everyone, and thank you for joining SWK Holdings First Quarter 2023 Financial and Corporate Results Call. Earlier this morning, SWK Holdings issued a press release detailing its financial results for the three months ended March 31st, 2023. The press release can be found in the Investor Relations section of swkhold.com under News Releases. Before beginning today's call, I would like to make a formal statement regarding forward-looking statements. Today, we'll be making certain forward-looking statements about future expectations, plans, events, and circumstances, including statements about our strategy, future operations, and the development of our consumer and drug product candidates, plans for future potential product candidates, and studies and expectations regarding our capital allocation and cash resources. These statements are based on current expectations and should not place undue reliance on these statements. Actual results may differ materially due to our risks and uncertainties, including those detailed in the Risk Factors section of SWK Holdings 10-K filed with the SEC and other filings we make with the SEC from time to time. SWK Holdings disclaims any obligation to update information contained in those forward-looking statements, whether as a result of new information, future events or otherwise. Joining me from SWK Holdings on today's call are Jody Staggs, President and CEO, and Yvette Heinrichsen, Chief Financial Officer. They'll provide an update on SWK's first quarter 2023 corporate and financial results. Jody, go ahead. Thank you, Jason, and thanks to everyone for joining our first quarter conference call. First quarter results were in line with our expectations as financial segment non-GAAP net income totaled $7.3 million, representing a 12% annualized return on tangible finance book value. This is a solid baseline return for our lending strategy, although we believe we can improve on this figure through continued diligent underwriting combined with appropriate balance sheet leverage. Our gross total investment assets reached an all-time high of $250 million, which is an increase from $238 million at the end of 2022 and $196 million at March 31, 2022. This quarter, we implemented the Current Expected Credit Losses model, better known as CECL. CECL implementation resulted in an $11.8 million allowance for credit losses, which bridges to the $238 million net total investment assets reported at period end. The CECL allowance is not allocated to a specific finance receivable, nor is driven by a view on any specific finance receivable. SWK worked with a consultant to calculate an appropriate CECL reserve using our historical loss rates as well as competitor loss rates. Through this analysis, we concluded an approximately 4% reserve against our funded and unfunded finance receivables is appropriate at this time. Based on our typical five-year loan maturity, this translates to a roughly 80 basis point per year loss rate. This allowance was charged to our accumulated deficit and, after adjusting for a change in our deferred tax asset, resulted in a $9.7 million reduction in book value. Our portfolio effective yield was 15.5%, up from 13.9% in first quarter of 2022 and around an all-time high. Our tailored financing solutions are well suited for the current market environment, and we're issuing new term sheets with a mid-to-high teens cost of capital. Turning to the portfolio credit quality, you will see in our 10-Q, we disclosed our internal credit scores for the first time. We score our loans one through five, with five being the highest score. With the exception of the $11.8 million Flowonix non-accrual position, all SWK loans are rated three or better as of the first quarter of 2023. We continue to work with Flowonix to achieve a resolution. We are also in regular communication with borrowers that will require additional funding during 2023. We score our royalties green, yellow and red. For the first quarter of 2023, 84% of our royalties were scored green. The $4.2 million Ideal royalty and the Legacy $2.9 million Best royalty are the majority of the non-green royalty positions. We are in regular communications with Ideal and working to achieve a resolution. The turnaround at our Enteris subsidiary continues with total Enteris operating expenses declining from $2.6 million in fourth quarter 2022 to $1.4 million as of first quarter 2023. While there will be one-time charges in the second quarter from former employee severance, current employee retention payments, some final R&D program costs and strategic review costs, the first quarter of 2023 OpEx run rate is a reasonable normalized operating expense level for Enteris. Additionally, we are excited with the $7 million of CDMO proposals Enteris has bid on year to date. A material portion of these bids were driven by our relationship with a large pharma service organization. While it's too early to forecast our close rate, these are warm leads, and we expect the strong pipeline to drive revenue growth in the second half of 2023. As previously discussed, we are working with an advisor to evaluate strategic alternatives for Enteris, and we'll provide an update when appropriate. During the quarter, we repurchased 28,766 shares through our 10b5-1 program, and year to date, we have repurchased nearly 50,000 shares. A minor correction from the press release. Post-quarter close, we repurchased over 18,000 shares for approximately $318,000 or $17.57 a share. I think the press release said $400,000. Our current program expires May 15th, and I expect our board will approve a new 10b5-1 program that we believe will have benefits over the old program, ideally allowing us to repurchase a greater number of shares. To summarize, the first quarter of 2023 was a solid quarter for our financial segment, with $7.3 million of segment adjusted net income, a very strong 12% return on book and a 15.5% effective yield. We are working with our two non-accrual borrowers to seek a positive resolution and are in regular communications with borrowers that need access to capital markets near term. The new loan environment is attractive, and we're pursuing balance sheet capital deploy into this opportunity. With that, I would like to turn the call to our CFO, Yvette Heinrichsen, for an update on our financial performance for the quarter. Yvette, the call is yours. Thank you, Jody, good morning, everyone. As you mentioned earlier this morning, we reported earnings for the first quarter of 2023. We reported GAAP pre-tax net income of $4.5 million, or $0.35 per diluted share. Our reported Q1 2023 net income of $4.6 after income tax benefit of $0.1 million included a $1.7 million decrease in finance receivables segment revenue and a $0.6 million decrease in our pharmaceutical development segment revenue. The decrease in year-over-year revenue included a $5.3 million decrease from finance receivables that were paid off in 2022. That included $2.4 million of revenue from the resolution of the B&D Dental loan in Q1 of 2022, as well as $1.4 million of royalties received on sales of NARCAN, which was sold in the fourth quarter of 2022. The decrease was partially offset by a $4.4 million increase in revenues received from new investments initiated over the past 12 months or additional funding extended to existing borrowers. Absent any material unforeseen payoffs, we anticipate that finance receivables revenue over the next 3 quarters of the year to be comparable to revenue reported in Q1 in 2023. Overall operating expenses during Q1 2023 decreased to $3.4 million from $5.1 million in Q1 of 2022. As Jody mentioned earlier, Enteris operating expenses decreased to $1.4 million in Q1 2023 from $2.6 million in Q1 2022. Finance receivables segment operating expenses decreased to $2.2 million in Q1 2023 from $2.2 million in Q1 2022. Again, as Jody mentioned, effective January 1, 2023, SWK adopted the Accounting Standards Update 2016-13, which requires companies to develop an expected credit loss methodology based on historical data combined with both current conditions and future developments. Upon adoption of the new accounting standard, we wrote off the full $11.8 million previously reported allowance for credit losses on specific finance receivables. Those receivables are now presented net of those previously reported allowances. We estimated expected credit losses using a loss rate model that utilizes publicly available data sources, current conditions, and qualitative forecasts that are reasonable and supportable as inputs. We then applied our loss rate model to our two portfolio segments to arrive at our current allowance for credit losses of, coincidentally, $11.8 million, which is presented as a reduction to finance receivables. We also recorded a $0.4 million liability for the unfunded commitments described in footnote six of our Q1 10-Q. The cumulative impact from the adoption of the accounting standard was recorded as a $9.77 million reduction, net of applicable deferred tax assets of $2.5 million to the accumulated deficit. Although the adoption of this accounting standard had a material impact to prior earnings, utilizing the expected credit loss model will allow for smoother financial reporting as it incrementally predicts non-performing loans and future write-offs that create volatility in financial reporting. With that, I will conclude by echoing Jody's remarks that the environment is as attractive as ever for high quality, well-priced deployment, and we are working hard to take advantage of that. I will now turn the call back over to Jody. Thanks, Yvette. In summary, the first quarter of 2023 was in line with our expectations, and we are pursuing our 2023 goals to position SWK for long-term shareholder value creation. Operator, let's open the call for questions. We will now begin the question and answer session. To ask a question, you may press star then one on your telephone keypad. If you're using a speaker phone, please pick up your handset before pressing the keys. If at any time your question has been addressed and you would like to withdraw your question, please press star then two. At this time, we will pause momentarily to assemble our roster. The first question comes from Mark Argento with Lake Street. Please go ahead. Hey, Jody and Yvette. Just a couple of quick questions. First off, I know, you know, you walked through the implementation of CECL. Just wanted to clarify, how are you doing kind of loan loss reserves previous? Were you haircutting specific loans, or was there a different way that you were accomplishing the same thing? Yeah. Let me give you sort of the high level, then I'll let Yvette speak to, you know, kind of the specific accounting treatment. Historically, we've been either impairing or reserving against specific loans or royalties once a loss, you know, is real or is anticipated. It was specific. We did have not historically had an unallocated sort of general loss bucket. That's really what the difference is here. Yvette, do you wanna comment or elaborate on that? Under the previous model for recognizing credit losses, it had to basically have been something that is likely to occur. It was really applied to a specific asset we knew that we were not going to get that is not paying according to the contractual terms. Now we have a general reserve that is applied to the entire portfolio. All right. That's, that's helpful. Jody- Martin, just one other comment, you know, it just because I know it's a little confusing, but I think the important thing is that this is an accounting, you know, it's an accounting pronouncement and something we have to implement. You know, it doesn't in any way, shape, or form, you know, reflect our view on the portfolio or expected losses. We needed to build this general reserve. You know, a lot of finance companies have been doing this, I think, really over the last three years, and it was time for us to implement this. Yeah. No, it makes sense. Just turning to just the general opportunity out there. Obviously, there's a need for capital, especially in the areas in which you guys focus on. You know, it looks like you made one new loan in the quarter, you know, extended some additional capital, some existing customers. What's kind of the dynamic right now in terms of the opportunity to deploy more capital? Dovetailing with that, you know, I know you guys have been hard at work at trying to, you know, source additional capital, add some leverage to the balance sheet. Maybe you could give us an update on both fronts there. Thanks. Yeah. Yeah, absolutely. You know, the opportunity set is quite interesting. The pipeline's good and all that. The challenge really has been that we're fairly deployed here. We've, you know, we've got the ability to do maybe a small deal or two, but it's challenging when you're at that level because we, you know, we have a business where we need to have a pipeline of opportunities ranging from first call to, you know, term sheet issued. When we're down to that level of capital, you know, it becomes challenging because you're sort of picking one of the opportunities to kind of commit to. If that opportunity doesn't move forward, you know, then you have to go back to kind of the mid-level of the pipeline, where we of course would not go out there and, you know, commit to situations where we don't have capital. We are building a little bit more capital now, so I think we've got some opportunities sort of regardless of what happens on our balance sheet to do a deal or two here going forward. On the raise side, on the balance sheet side, you know, I personally am, you know, frustrated that we have not been able to, you know, announce anything to this point. We've it's a little challenging to sort of answer that question because we've of course been very active and have pursued a few different options. You know, the regional bank turmoil has been a challenge, one that we're gonna overcome, and I'm confident we're gonna get this done. You know, we're working with a variety of parties and some of those parties have had internal problems. Right now I feel really good about where we are. We're working on a specific project to get this done. I can't really say anything else. I certainly don't wanna overpromise in this environment. We will get this done. It's gonna happen. It's just a matter of when. Ideally, you know, we're gonna have additional capacity on our ABL, which is, you know, most cost-effective and structurally effective piece of capital. Then we'll look at other things as well. You know, I think we've discussed previously, we've looked at, you know, unsecured bonds and things like that. It's gonna happen. You know, the exact timing, you know, remains a bit TBD. Once that happens and we have, you know, material additional capital, I think you'll see us close, you know, more loans. We'll be able to kind of run the business, the new development and the business development portion of the business more effectively. Great. Thanks for the color. Good luck. Thank you. If you'd like to ask a question, please press star then one. The next question comes from Scott Jensen, a private investor. Please go ahead. Hey, good morning, Jody. I have a question. Just how do you kind of view or prepare for the possible maybe new regime in the market for companies raising capital, since it often appears that you're kind of that bridge until they get that next set of financing? How do you kind of protect yourself or view that development? Yes. Let me take a stab at that and, kind of make sure I'm answering the right question. That's correct. You know, we identify differentiated life science product companies. We're advancing them capital and, our capital needs to be used to, you know, really increase value. All of our companies at some point in time are likely gonna need to raise additional capital or look for some type of exit. You know, in one sense, that's our business. That's always been our business. The capital we put in ideally is bridging them to that and bridging them close to cash flow break-even. The market's, of course, tougher for folks raising capital. I think everyone here knows that. You know, to answer your question, I think we're trying to get out in front of the situations where the near-term need for capital is, you know, more obvious and maybe a little more stressed, and that may be through amendments. With those amendments, we may be requiring certain things, you know, probably a little bit more regular communications and trying to be a little bit more diligent and thoughtful about, you know, how we're working with those situations. That's kind of the existing portfolio. You know, the new deal portfolio, we're really trying to focus on opportunities that our capital's bridging to cash flow positive, and there's equity coming in, and we're looking for runways, you know, much longer than maybe we have historically. We're looking for, you know, 18 months plus, whereas historically I think we've been much more comfortable in shorter runways. Okay, great. My last question is just you had mentioned, possible increase in costs just for the second quarter for Enteris. Do you have like an approximate range about what that might be? Like half a million, $4 million, $2 million? No, no, no, no. It won't, it won't be that much. We're, we're talking about hundreds of thousands of dollars here. I don't have that number in front of me. It's kind of a handful of things going on. You know, we mentioned some one-timers. There's some former severance costs. There are a few retention payments. You know, we're running the strategic process, so we've got costs associated with that. But I think you'll see, you know, a tweak in the second quarter, but once we get past all of that, I think this $1.4 million-$1.5 million, you know, OpEx number, and that's all in, at Enteris, that's everything. You know, I think we feel really good about that. The only way I would expect it to change going forward is if, you know, they just continue doing so well on the revenue front, have to bring on, you know, a little bit of additional help. Understood. Just one more. It would be a statement rather than a question, and that is just I would keep advising more aggressive buying back the stock, and I'm glad that you're thinking about expanding the program in that fashion. Thank you. Yeah. No, appreciate that. You know, we think at this level it's a really, you know, solid use of capital. It hasn't been as easy as I think all of us would've hoped. We do think that, you know, our oral 10b5-1 maybe was a bit suboptimal and that we can improve that. Yeah, I won't go into specifics, but there's We, you know, we've spoken with new council and things. I think step one is really, you know, getting that program optimized and seeing what happens there. Hear you, agreed, and appreciate that sentiment. Great. Thanks so much. This concludes our question and answer session. I would like to turn the conference back over to Jody Staggs for any closing remarks. Thank you, operator. Thank you, Jason. Thank you, Yvette. Appreciate everyone dialing in and the questions. Yvette and I will be around today, tomorrow. Feel free to reach out if you would like to discuss or have any questions on the results. Thanks. I hope everyone has a great day. Bye-bye. The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.